Derik De Bruin
Stock Analyst at B of A Securities
(4.66)
# 198
Out of 4,732 analysts
205
Total ratings
68.79%
Success rate
15.17%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Upgrades: Buy | $138 | $118.39 | +16.56% | 2 | Dec 13, 2024 | |
| TMO Thermo Fisher | Maintains: Buy | $675 → $660 | $559.65 | +17.93% | 18 | Dec 13, 2024 | |
| MYGN Myriad Genetics | Maintains: Underperform | $15 → $13 | $12.39 | +4.92% | 12 | Dec 13, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $235 | $197.36 | +19.07% | 3 | Dec 13, 2024 | |
| EXAS Exact Sciences | Maintains: Buy | $75 → $72 | $51.74 | +39.16% | 6 | Dec 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $220 → $210 | $163.50 | +28.44% | 5 | Dec 13, 2024 | |
| A Agilent Technologies | Maintains: Neutral | $153 → $150 | $147.36 | +1.79% | 31 | Dec 13, 2024 | |
| WAT Waters | Maintains: Neutral | $400 → $430 | $404.00 | +6.44% | 12 | Dec 13, 2024 | |
| WST West Pharmaceutical Services | Maintains: Buy | $350 → $355 | $336.34 | +5.55% | 7 | Dec 13, 2024 | |
| STVN Stevanato Group | Maintains: Buy | $24 → $26 | $22.85 | +13.79% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $19 | $14.21 | +33.71% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $238.56 | +13.60% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $151.20 | +20.37% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $56.88 | +40.65% | 12 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $238.36 | +21.66% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $20.82 | -27.95% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $17.69 | +18.71% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $25 | $15.08 | +65.78% | 8 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $19.00 | +68.42% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $136.67 | -26.83% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $69.73 | +23.33% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $4.11 | +216.30% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,650 → $1,525 | $1,295.43 | +17.72% | 9 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.29 | +183.84% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $198.11 | +31.24% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $10.83 | +1,008.03% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $61 | $46.00 | +32.11% | 5 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $165.89 | -27.66% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $3.08 | +192.21% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $419.26 | -43.95% | 3 | Nov 2, 2018 |
Revvity
Dec 13, 2024
Upgrades: Buy
Price Target: $138
Current: $118.39
Upside: +16.56%
Thermo Fisher
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $559.65
Upside: +17.93%
Myriad Genetics
Dec 13, 2024
Maintains: Underperform
Price Target: $15 → $13
Current: $12.39
Upside: +4.92%
IQVIA Holdings
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $197.36
Upside: +19.07%
Exact Sciences
Dec 13, 2024
Maintains: Buy
Price Target: $75 → $72
Current: $51.74
Upside: +39.16%
Charles River Laboratories International
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $163.50
Upside: +28.44%
Agilent Technologies
Dec 13, 2024
Maintains: Neutral
Price Target: $153 → $150
Current: $147.36
Upside: +1.79%
Waters
Dec 13, 2024
Maintains: Neutral
Price Target: $400 → $430
Current: $404.00
Upside: +6.44%
West Pharmaceutical Services
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $336.34
Upside: +5.55%
Stevanato Group
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $22.85
Upside: +13.79%
Dec 13, 2024
Maintains: Neutral
Price Target: $18 → $19
Current: $14.21
Upside: +33.71%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $238.56
Upside: +13.60%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $151.20
Upside: +20.37%
Dec 13, 2024
Maintains: Buy
Price Target: $78 → $80
Current: $56.88
Upside: +40.65%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $238.36
Upside: +21.66%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $20.82
Upside: -27.95%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $17.69
Upside: +18.71%
Jul 18, 2024
Maintains: Neutral
Price Target: $36 → $25
Current: $15.08
Upside: +65.78%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $19.00
Upside: +68.42%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $136.67
Upside: -26.83%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $69.73
Upside: +23.33%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $4.11
Upside: +216.30%
May 8, 2023
Maintains: Neutral
Price Target: $1,650 → $1,525
Current: $1,295.43
Upside: +17.72%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.29
Upside: +183.84%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $198.11
Upside: +31.24%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $10.83
Upside: +1,008.03%
Oct 6, 2020
Upgrades: Buy
Price Target: $61
Current: $46.00
Upside: +32.11%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $165.89
Upside: -27.66%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $3.08
Upside: +192.21%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $419.26
Upside: -43.95%